Table 1 |
|
Major themes around restricted access to tumour necrosis factor inhibitors |
| Predetermined Interview topics |
| Perceptions of PBS-restrictions on access |
| Experience with application process |
| Pre-PBS collaboration between the different stakeholder groups |
| Post-PBS collaboration between the different stakeholder groups |
| Sources of information |
| Major themes emerging from data |
| Access to medicines |
| Targeting access |
| Review of the PBS-restrictions |
| Implications of access arrangements in practice |
| Effects on the practice of rheumatology |
| Ethical issues |
| Roles and responsibilities |
| PBS Decision-making process |
| Stakeholder consultation process |
| Transparency |
| Information provision |
|
|
|
Lu et al. Australia and New Zealand Health Policy 2005 2:28 doi:10.1186/1743-8462-2-28 |
